This Article  • Full text  • PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (18)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Neurology  • Alzheimer Disease  • Alert me on articles by topic  Social Bookmarking   What's this?

What's Next?

Lenore J. Launer, PhD

JAMA. 2003;289:2865-2867.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In this issue of THE JOURNAL, Aisen and colleagues¹ from the Alzheimer's Disease Cooperative Study (ADCS) report the results of a 1-year double-blind, placebo-controlled randomized trial designed to test whether 2 nonsteroidal anti-inflammatory drugs (NSAIDs), naproxen and rofecoxib, slowed cognitive decline in patients with mild to moderate Alzheimer disease (AD). These NSAIDs were tested separately against their own placebo, and the authors used several analytical strategies to test for an effect. The primary outcome measure (Alzheimer Disease Assessment Scale-cognitive subscale [ADAS-Cog] score, which measures the cognitive domains impaired in AD) showed no difference between the placebo and treatment groups with either of the NSAIDs. Similarly, the secondary outcomes (measures of activities of daily living, quality of life, and time to institutionalization or death) showed no evidence of a treatment effect.

NSAIDs were selected as a candidate drug for the treatment of AD based on the evidence . . . [Full Text of this Article]

Author Affiliation: Neuroepidemiology Section, Laboratory for Epidemiology, Demography, Biometry, National Institute on Aging, Bethesda, Md.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Effects of Rofecoxib or Naproxen vs Placebo on Alzheimer Disease Progression: A Randomized Controlled Trial
Paul S. Aisen, Kimberly A. Schafer, Michael Grundman, Eric Pfeiffer, Mary Sano, Kenneth L. Davis, Martin R. Farlow, Shelia Jin, Ronald G. Thomas, and Leon J. Thal
JAMA. 2003;289(21):2819-2826.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Reverse remodelling in heart failure with cardiac resynchronisation therapy
Sutton and Keane
Heart 2007;93:167-171.
ABSTRACT | FULL TEXT  

William M. Feinberg Lecture: Cognitive Vitality and the Role of Stroke and Cardiovascular Disease Risk Factors
Gorelick
Stroke 2005;36:875-879.
ABSTRACT | FULL TEXT  

Curcumin Inhibits Formation of Amyloid {beta} Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo
Yang et al.
J. Biol. Chem. 2005;280:5892-5901.
ABSTRACT | FULL TEXT  

Risk Factors for Vascular Dementia and Alzheimer Disease
Gorelick
Stroke 2004;35:2620-2622.
ABSTRACT | FULL TEXT  

No Benefit of (Some) NSAIDs in Alzheimer's Disease Progression
JWatch Neurology 2003;2003:6-6.
FULL TEXT  

No Benefit of (Some) NSAIDs in Alzheimer's Disease Progression
JWatch Psychiatry 2003;2003:10-10.
FULL TEXT  

No Benefit of (Some) NSAIDs in Alzheimer's Disease Progression
JWatch Gastroenterology 2003;2003:9-9.
FULL TEXT  

No Benefit of (Some) NSAIDs in Alzheimer's Disease Progression
JWatch General 2003;2003:1-1.
FULL TEXT